- Home
- HUM vs TEVA Comparison
HUM vs TEVA Comparison
Compare HUM & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUM | TEVA |
|---|---|---|
| Founded | 1961 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.3B | 39.2B |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | HUM | TEVA |
|---|---|---|
| Price | $389.51 | $33.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 20 | 8 |
| Target Price | ★ $238.65 | $38.63 |
| AVG Volume (30 Days) | 1.1M | ★ 5.7M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 9.83 | N/A |
| Revenue | ★ $129,664,000,000.00 | N/A |
| Revenue This Year | $26.15 | N/A |
| Revenue Next Year | $6.07 | $2.97 |
| P/E Ratio | $39.07 | ★ $28.19 |
| Revenue Growth | ★ 10.11 | N/A |
| 52 Week Low | $163.11 | $14.99 |
| 52 Week High | $385.49 | $37.35 |
Technical Indicators
Market Signals| Indicator | HUM | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 76.83 | 48.87 |
| Support Level | $249.64 | $30.59 |
| Resistance Level | N/A | $35.33 |
| Average True Range (ATR) | 12.13 | 1.11 |
| MACD | -1.72 | -0.01 |
| Stochastic Oscillator | 95.90 | 58.20 |
Price Performance
Historical ComparisonAbout HUM Humana Inc.
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.